PROGRAM FACULTY
Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan
Laura Bush, DMSc, PA-C, DFAAPA
Physician Assistant
Fayette Area Dermatology
Fayetteville, Georgia
PROGRAM OVERVIEW
This educational symposium is designed to equip healthcare professionals with the skills and knowledge necessary to optimize the management of patients with psoriasis (PsO). Attendees will learn to implement comprehensive assessment tools to evaluate disease severity and determine eligibility for systemic therapy accurately. The symposium will also explore current guideline recommendations alongside efficacy and safety data to support evidence-based selection among a broad and evolving array of treatment options, including emerging oral therapies. Additionally, attendees will be guided in designing individualized treatment plans through effective shared decision-making strategies that align with patient preferences and clinical goals.
TARGET AUDIENCE
This educational activity is specifically designed for dermatology NPs and PAs, and dermatologists involved in the management of patients with plaque psoriasis.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement comprehensive assessment tools in practice to determine disease severity and systemic therapy eligibility of patients with PsO
- Analyze guideline recommendations and efficacy and safety data supporting the numerous options within the evolving PsO treatment landscape, including emerging oral options
- Design individualized PsO treatment plans utilizing shared decision-making
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
AAPA CREDIT DESIGNATION STATEMENT – ENDURING MATERIALS
Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.
This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 11/26/2026. PAs should only claim credit commensurate with the extent of their participation.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Linda Stein Gold, MD | Consulting Fees, Speakers Bureaus and Contracted Research: AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, Lilly, and Takeda Pharmaceuticals |
| Laura Bush, DMSc, PA-C, DFAAPA | Consulting Fees: Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Janssen Pharmaceuticals, Johnson & Johnson, L’Oréal, Ortho Dermatologics, Sanofi, and Takeda Pharmaceuticals Speakers Bureaus: Boehringer Ingelheim, Ferndale Laboratories, and UCB Stock: Bristol Myers Squibb, and Vertex Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Laura Sevrinsky, medical reviewer, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Jessica McMullen, MPH, Program Director for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 26, 2025
EXPIRATION DATE: November 26, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
